Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baofukang and Dingjunsheng for Persistent HPV Infection
NCT06467942Recruiting
- Sponsor
- Peking University People's Hospital
- Start
- Mar 2023
- Primary completion
- Dec 2024
- Modality
- Implantable Devices, Transdermal Patches, Inhalation Devices
- Countries
- 1
01
Overview
Randomised, double-blind trial of baofukang shuan and lactobacillus crispatus in human papillomavirus infection (4 arms), sponsored by Peking University People's Hospital. Primary endpoints: Community State Type at 12 months, HPV Viral Load at 12 months and 1 more. Started Mar 2023; status: recruiting.
02
Drugs
baofukang shuanlactobacillus crispatus
03
Conditions
human papillomavirus infection
Beyond the preview
Go deeper on NCT06467942.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06467942.